MedTrace Logo

A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

NCT05381909 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2026-02-20

No results posted yet for this study

Summary

This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered dose of BGB-24714. Additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

BGB-24714

administered orally

DRUG

Paclitaxel

administered intravenously

DRUG

Carboplatin

administered intravenously

DRUG

Docetaxel

administered intravenously

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-06
Primary Completion
2025-07-25
Completion
2025-07-25
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China
  • New Zealand
  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05381909 on ClinicalTrials.gov